GlassScriptPhysician profile
Melissa A Rodriguez
NPI 1063898922
$7,176.54
in general payments reported to CMS, 2019-2025
51 companies · $2,881 in 2025
The $2,881 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,059 · 2022: $965 · 2023: $882 · 2024: $1,389 · 2025: $2,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,874 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,874.06 |
| Education | $278.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $636.02 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Daiichi Sankyo INC. | $447.61 | 2021-2025 | Enhertu, Vanflyta |
| Myriad Genetic Laboratories, INC. | $422.36 | 2021-2025 | Myrisk |
| E.R. Squibb & Sons, L.L.C. | $357.38 | 2021-2025 | Opdivo |
| Abbvie INC. | $346.16 | 2021-2025 | |
| Janssen Biotech, INC. | $321.88 | 2022-2025 | Darzalex, Carvykti, Rybrevant |
| Puma Biotechnology, INC. | $320.50 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $301.48 | 2022-2025 | Imfinzi, Lynparza, Calquence |
| Gilead Sciences, INC. | $272.80 | 2022-2025 | Trodelvy |
| Pfizer INC. | $246.34 | 2021-2025 | |
| Sobi, INC | $238.51 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $223.68 | 2022-2025 | Libtayo, Lynozyfic |
| Lilly USA, LLC | $190.56 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $190.18 | 2024-2025 | |
| Glaxosmithkline, LLC. | $181.23 | 2021-2025 | Ojjaara |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.